

(FILE 'HOME' ENTERED AT 11:22:41 ON 05 FEB 2007)

FILE 'REGISTRY' ENTERED AT 11:22:57 ON 05 FEB 2007

L1 1 S KETAMINE/CN

FILE 'CAPLUS' ENTERED AT 11:23:09 ON 05 FEB 2007

L2 1314 S L1/THU

L3 93 S L2 AND DEPRESSION

L4 1 S L3 AND ANTIPSYCHOTIC

L5 2 S L3 AND (ZIPRASIDONE OR ARIPIPRAZOLE OR PERPHENAZINE OR TRIPFL

FILE 'USPATFULL' ENTERED AT 11:25:06 ON 05 FEB 2007

L6 176 S L1

L7 65 S L6 AND DEPRESSION

L8 6 S L7 AND (ZIPRASIDONE OR ARIPIPRAZOLE OR PERPHENAZINE OR TRIPFL

FILE 'PCTFULL' ENTERED AT 11:26:11 ON 05 FEB 2007

L9 0 S KETAMINEAND DEPRESSION

L10 1046 S KETAMINE AND DEPRESSION

L11 149 S L10 AND (ZIPRASIDONE OR ARIPIPRAZOLE OR PERPHENAZINE OR TRIPF

L12 45 S L11 NOT PY>2002

L13 33 S L12 AND ANTIPSYCHOTIC

=> file registry
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 11:22:57 ON 05 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 FEB 2007 HIGHEST RN 919280-84-5
DICTIONARY FILE UPDATES: 4 FEB 2007 HIGHEST RN 919280-84-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s ketamine/cn
L1 1 KETAMINE/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 6740-88-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN Cyclohexanone, 2-(2-chlorophenyl)-2-(methyamino)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclohexanone, 2-(2-chlorophenyl)-2-(methyamino)-, (+)-
CN Cyclohexanone, 2-(o-chlorophenyl)-2-(methyamino)-, (+)- (8CI)
OTHER NAMES:
CN (+)-2-(o-Chlorophenyl)-2-(methyamino)cyclohexanone
CN (+)-Ketamine
CN dl-Ketamine
CN Ketamine
CN Ketoject
CN NSC 70151
CN Vetaset
DR 79499-51-7, 33643-45-7, 100477-72-3
MF C13 H16 Cl N O
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
MRCK*, PHAR, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2,
USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3882 REFERENCES IN FILE CA (1907 TO DATE)
 23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3895 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.35

7.56

FILE 'CAPLUS' ENTERED AT 11:23:09 ON 05 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Feb 2007 VOL 146 ISS 7

FILE LAST UPDATED: 4 Feb 2007 (20070204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L1/thu

3895 L1

853067 THU/RL

L2

1314 L1/THU

(L1 (L) THU/RL)

=> s l2 and depression

80829 DEPRESSION

L3

93 L2 AND DEPRESSION

=> s l3 and antipsychotic

9509 ANTIPSYCHOTIC

L4

1 L3 AND ANTIPSYCHOTIC

=> d l4 ti ans bib

'ANS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):ti abs bib

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Use of N-desmethylozapine to treat human neuropsychiatric disease
 AB Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylozapine to a patient suffering from a neuropsychiatric disease.
 AN 2005:349001 CAPLUS <<LOGINID::20070205>>
 DN 142:386016
 TI Use of N-desmethylozapine to treat human neuropsychiatric disease
 IN Weiner, David M.; Brann, Mark R.
 PA USA
 SO U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S Ser. No. 761,787.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005085463	A1	20050421	US 2004-913117	20040805
	US 2004224942	A1	20041111	US 2004-761787	20040121
	US 2005250767	A1	20051110	US 2005-98892	20050404
	WO 2006017614	A1	20060216	WO 2005-US27645	20050804
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006194831	A1	20060831	US 2006-416565	20060503
	US 2006199807	A1	20060907	US 2006-417069	20060503
PRAI	US 2003-442690P	P	20030123		
	US 2004-761787	A2	20040121		
	US 2004-913117	A2	20040805		
	US 2004-617553P	P	20041008		
	US 2005-98892	A	20050404		

=> s l3 and (ziprasidone or aripiprazole or perphenazine or tripfluophenazine or zotepine or flupenthixol or amisulpride or sulpride)

683 ZIPRASIDONE
 430 ARIPIPAZOLE
 1538 PERPHENAZINE
 0 TRIPFLUOPHENAZINE
 235 ZOTEPINE
 5 FLUPHENTHIXOL
 310 AMISULPRIDE
 26 SULPRIDE

L5 2 L3 AND (ZIPRASIDONE OR ARIPIPAZOLE OR PERPHENAZINE OR TRIPFLUOPHENAZINE OR ZOTEPINE OR FLUPHENTHIXOL OR AMISULPRIDE OR SULPRIDE

=> d l5 1-2 ti abs bib

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Use of N-desmethylozapine to treat human neuropsychiatric disease
 AB Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount

of N-desmethyloclozapine to a patient suffering from a neuropsychiatric disease.

AN 2005:1200866 CAPLUS <<LOGINID::20070205>>
DN 143:452893
TI Use of N-desmethyloclozapine to treat human neuropsychiatric disease
IN Weiner, David M.; Brann, Mark R.
PA USA
SO U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 913,117.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005250767	A1	20051110	US 2005-98892	20050404
	US 2004224942	A1	20041111	US 2004-761787	20040121
	US 2005085463	A1	20050421	US 2004-913117	20040805
	WO 2006017614	A1	20060216	WO 2005-US27645	20050804
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006194831	A1	20060831	US 2006-416565	20060503
	US 2006199807	A1	20060907	US 2006-417069	20060503
PRAI	US 2003-442690P	P	20030123		
	US 2004-761787	A2	20040121		
	US 2004-913117	A2	20040805		
	US 2004-617553P	P	20041008		
	US 2005-98892	A	20050404		

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Use of N-desmethyloclozapine to treat human neuropsychiatric disease
AB Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethyloclozapine to a patient suffering from a neuropsychiatric disease.

AN 2005:349001 CAPLUS <<LOGINID::20070205>>
DN 142:386016
TI Use of N-desmethyloclozapine to treat human neuropsychiatric disease
IN Weiner, David M.; Brann, Mark R.
PA USA
SO U.S. Pat. Appl. Publ., 34 pp., Cont.-in-part of U.S. Ser. No. 761,787.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005085463	A1	20050421	US 2004-913117	20040805
	US 2004224942	A1	20041111	US 2004-761787	20040121
	US 2005250767	A1	20051110	US 2005-98892	20050404
	WO 2006017614	A1	20060216	WO 2005-US27645	20050804
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

US 2006194831	A1	20060831	US 2006-416565	20060503
US 2006199807	A1	20060907	US 2006-417069	20060503
PRAI US 2003-442690P	P	20030123		
US 2004-761787	A2	20040121		
US 2004-913117	A2	20040805		
US 2004-617553P	P	20041008		
US 2005-98892	A	20050404		

=> file uspatfull
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
32.01	39.57

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.34	-2.34

CA SUBSCRIBER PRICE

FILE 'USPATFULL' ENTERED AT 11:25:06 ON 05 FEB 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Feb 2007 (20070201/PD)
 FILE LAST UPDATED: 1 Feb 2007 (20070201/ED)
 HIGHEST GRANTED PATENT NUMBER: US7171694
 HIGHEST APPLICATION PUBLICATION NUMBER: US2007028338
 CA INDEXING IS CURRENT THROUGH 1 Feb 2007 (20070201/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Feb 2007 (20070201/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2006
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2006

=> s 11

L6 176 L1

=> s 16 and depression

149594 DEPRESSION

L7 65 L6 AND DEPRESSION

=> s 17 and (ziprasidone or aripiprazole or perphenazine or tripfluophenazine or
 zotepine or fluphenthixol or amisulpride or sulpride)

637 ZIPRASIDONE

292 ARIPIPAZOLE

1512 PERPHENAZINE

0 TRIPFLUOPHENAZINE

214 ZOTEPINE

24 FLUPHENTHIXOL

185 AMISULPRIDE

68 SULPRIDE

L8 6 L7 AND (ZIPRASIDONE OR ARIPIPAZOLE OR PERPHENAZINE OR TRIPFLUOP
 HENAZINE OR ZOTEPINE OR FLUPHENTHIXOL OR AMISULPRIDE OR SULPRIDE

=> d 18 1-6 ti

L8 ANSWER 1 OF 6 USPATFULL on STN

TI Use of N-desmethyloclozapine to treat human neuropsychiatric disease

L8 ANSWER 2 OF 6 USPATFULL on STN
TI Use of N-desmethyldiclozpine to treat human neuropsychiatric disease

L8 ANSWER 3 OF 6 USPATFULL on STN
TI Topical compositions and methods for treating pain

L8 ANSWER 4 OF 6 USPATFULL on STN
TI Sterile, breathable patch for treating wound pain

L8 ANSWER 5 OF 6 USPATFULL on STN
TI Topical compositions and methods for treating pain

L8 ANSWER 6 OF 6 USPATFULL on STN
TI Dextromethorphan potentiator for anticonvulsant composition and method

=> d 18 3-6 ti abs bib

L8 ANSWER 3 OF 6 USPATFULL on STN
TI Topical compositions and methods for treating pain
AB Topical compositions and methods for treating pain. The invention provides oil-in-water emulsions comprising an antidepressant; an NMDA-receptor antagonists; a lipophilic component; water; and a surfactant. The compositions induce a local-anesthetic effect when topically administered to intact skin thereby treating or preventing pain, for example, neuropathic pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:100787 USPATFULL <<LOGINID::20070205>>
TI Topical compositions and methods for treating pain
IN Williams, Robert O., Austin, TX, UNITED STATES
Zhang, Feng, Austin, TX, UNITED STATES
PA EpiCept Corporation (U.S. corporation)
PI US 2004076648 A1 20040422
AI US 2003-669258 A1 20030925 (10)
RLI Continuation of Ser. No. US 2001-931293, filed on 17 Aug 2001, GRANTED,
Pat. No. US 6638981
DT Utility
FS APPLICATION
LREP JONES DAY, 51 Louisiana Aveue, N.W, WASHINGTON, DC, 20001-2113
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2001

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 6 USPATFULL on STN
TI Sterile, breathable patch for treating wound pain
AB An intradermal patch having a permeable backing coated with a polyvinylpyrrolidone-based hydrogel and containing one or more local anesthetics. The patch is breathable, non-irritating upon application and removal, soothing, and sterile. The patch is useful for treating the pain associated with non-intact skin indications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:119740 USPATFULL <<LOGINID::20070205>>
TI Sterile, breathable patch for treating wound pain
IN Mason, Paul Arthur, Flemington, NJ, UNITED STATES
PI US 2003082225 A1 20030501
AI US 2001-45730 A1 20011019 (10)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711

CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1480
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 6 USPATFULL on STN
TI Topical compositions and methods for treating pain
AB Topical compositions and methods for treating pain. The invention provides oil-in-water emulsions comprising an antidepressant; an NMDA-receptor antagonists; a lipophilic component; water; and a surfactant. The compositions induce a local-anesthetic effect when topically administered to intact skin thereby treating or preventing pain, for example, neuropathic pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:119729 USPATFULL <<LOGINID::20070205>>
TI Topical compositions and methods for treating pain
IN Williams, Robert O., Austin, TX, UNITED STATES
Zhang, Feng, Austin, TX, UNITED STATES
PI US 2003082214 A1 20030501
US 6638981 B2 20031028
AI US 2001-931293 A1 20010817 (9)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2008
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 6 USPATFULL on STN
TI Dextromethorphan potentiator for anticonvulsant composition and method
AB A pharmaceutical composition comprises an anti-epileptic drug that does not inhibit, enhance or otherwise modify dextromethorphan binding to the central nervous system dextromethorphan receptor and an effective amount of dextromethorphan to potentiate the anticonvulsant activity of the drug. Other related compounds similar to dextromethorphan which inhibit or enhance dextromethorphan binding to the dextromethorphan site in the brain are also suitable as potentiating agents for the anticonvulsants. A method of treating epilepsy and other convulsions include the steps of introducing to the patient an effective amount of the compound comprising an anti-epileptic drug and potentiating amount of dextromethorphan or one of the related compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 90:17687 USPATFULL <<LOGINID::20070205>>
TI Dextromethorphan potentiator for anticonvulsant composition and method
IN Pontecorvo, Michael J., Belcamp, MD, United States
Ferkany, John W., Baltimore, MD, United States
PA Nova Pharmaceutical Corporation, Baltimore, MD, United States (U.S. corporation)
PI US 4906638 19900306
AI US 1987-136751 19871222 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Friedman, Stanley J.
LREP Breneman & Georges
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file pctfull
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
10.96	50.53

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
0.00	-2.34

CA SUBSCRIBER PRICE

FILE 'PCTFULL' ENTERED AT 11:26:11 ON 05 FEB 2007
COPYRIGHT (C) 2007 Univentio

FILE LAST UPDATED: 29 JAN 2007 <20070129/UP>
MOST RECENT UPDATE WEEK: 200704 <200704/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s ketamineand depression
0 KETAMINEAND
38749 DEPRESSION
L9 0 KETAMINEAND DEPRESSION
(KETAMINEAND(W) DEPRESSION)

=> s ketamine and depression
5325 KETAMINE
38749 DEPRESSION
L10 1046 KETAMINE AND DEPRESSION

=> s l10 and (ziprasidone or aripiprazole or perphenazine or tripfluophenazine or
zotepine or flupenthixol or amisulpride or sulpride)
606 ZIPRASIDONE
315 ARIPIPAZOLE
986 PERPHENAZINE
0 TRIPFLUOPHENAZINE
134 ZOTEPINE
15 FLUPHENTHIXOL
195 AMISULPRIDE
50 SULPRIDE
L11 149 L10 AND (ZIPRASIDONE OR ARIPIPAZOLE OR PERPHENAZINE OR TRIPFLUO
PHENAZINE OR ZOTEPINE OR FLUPHENTHIXOL OR AMISULPRIDE OR SULPRID
E)

=> s l11 not py>2002
498579 PY>2002
L12 45 L11 NOT PY>2002

=> S L12 AND ANTIPSYCHOTIC
2759 ANTIPSYCHOTIC
L13 33 L12 AND ANTIPSYCHOTIC

=> D L13 1-33 TI

L13 ANSWER 1 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN HUMAN SECRETED PROTEINS
TIFR PROTEINES SECRETEES PAR L'HOMME

L13 ANSWER 2 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN HUMAN SECRETED PROTEINS
TIFR PROTEINES SECRETEES HUMAINES

L13 ANSWER 3 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN

TIEN	83 HUMAN SECRETED PROTEINS
TIFR	83 PROTEINES SECRETEES HUMAINES
L13	ANSWER 4 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS
TIFR	UTILISATION D'ANTAGONISTES DU RECEPTEUR GAL3 DANS LE TRAITEMENT DE LA DEPRESSION ET/OU DE L'ANXIETE ET COMPOSES UTILES DANS DE TELLES METHODES
L13	ANSWER 5 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	PULMONARY DELIVERY IN TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
TIFR	ADMINISTRATION PULMONAIRE DESTINEE AU TRAITEMENT DE TROUBLES DU SYSTEME NERVEUX CENTRAL
L13	ANSWER 6 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	17 HUMAN SECRETED PROTEINS
TIFR	17 PROTEINES HUMAINES SECRETEES
L13	ANSWER 7 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	7 HUMAN SECRETED PROTEINS
TIFR	7 PROTEINES HUMAINES SECRETEES
L13	ANSWER 8 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	11 HUMAN SECRETED PROTEINS
TIFR	11 PROTEINES HUMAINES SECRETEES
L13	ANSWER 9 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	21 HUMAN SECRETED PROTEINS
TIFR	21 PROTEINES HUMAINES SECRETEES
L13	ANSWER 10 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	12 HUMAN SECRETED PROTEINS
TIFR	12 PROTEINES HUMAINES SECRETEES
L13	ANSWER 11 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	8 HUMAN SECRETED PROTEINS
TIFR	HUIT PROTEINES SECRETEES HUMAINES
L13	ANSWER 12 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF
TIFR	ADN CODANT POUR UN RECEPTEUR HUMAIN DE L'HORMONE DE CONCENTRATION DE LA MELANINE (MCH1) ET SES APPLICATIONS
L13	ANSWER 13 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	29 HUMAN SECRETED PROTEINS
TIFR	29 PROTEINES HUMAINES SECRETEES
L13	ANSWER 14 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	7 HUMAN OVARIAN AND OVARIAN CANCER ASSOCIATED PROTEINS
TIFR	7 PROTEINES HUMAINES OVARIENNES ET PROTEINES ASSOCIEES AU CANCER DES OVAIRES
L13	ANSWER 15 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
TIFR	ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS
L13	ANSWER 16 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
TIFR	ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS
L13	ANSWER 17 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN	NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTIGENES

L13 ANSWER 18 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 19 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 20 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 21 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 22 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 23 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 24 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN ENDOCRINE RELATED NUCLEIC ACIDS, PROTEINS AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 25 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 26 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 27 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 28 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 29 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 30 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 31 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
 TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L13 ANSWER 32 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN 22 HUMAN SECRETED PROTEINS
 TIFR 22 PROTEINES HUMAINES SECRETEES

L13 ANSWER 33 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS

TIFR TRAITEMENT DE LA SCHIZOPHRENIE PAR AMPAKINES ET NEUROLEPTIQUES

=> D L13 4 33 TI ABS BIB

L13 ANSWER 4 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
 TIEN USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION
 AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS
 TIFR UTILISATION D'ANTAGONISTES DU RECEPTEUR GAL3 DANS LE TRAITEMENT DE LA
 DEPRESSION ET/OU DE L'ANXIETE ET COMPOSES UTILES DANS DE TELLES
 METHODES
 ABEN This invention is directed to pyrimidine and indolone derivatives which
 are selective antagonists for the GAL3 receptor. The invention provides
 a pharmaceutical composition comprising a therapeutically effective
 amount of a compound of the invention and a pharmaceutically acceptable
 carrier. This invention also provides a pharmaceutical composition made
 by combining a therapeutically effective amount of a compound of the
 invention and a pharmaceutically acceptable carrier. This invention
 further provides a process for making a pharmaceutical composition
 comprising combining a therapeutically effective amount of a compound of
 the invention and a pharmaceutically acceptable carrier. This invention
 also provides a method of treating a subject suffering from
 depression and/or anxiety which comprises administering to the
 subject an amount of a compound of the invention effective to treat the
 subject's depression and/or anxiety. This invention also
 provides a method of treating depression and/or anxiety in a
 subject which comprises administering to the subject a composition
 comprising a pharmaceutically acceptable carrier and a therapeutically
 effective amount of a GAL3 receptor antagonist.
 ABFR Cette invention concerne des derives de pyrimidine et d'indolone
 lesquels sont des antagonistes selectifs du recepteur GAL3. L'invention
 concerne une composition pharmaceutique contenant une dose therapeutique
 efficace d'un compose de l'invention et un excipient pharmaceutiquement
 acceptable. Cette invention concerne egalement une composition
 pharmaceutique obtenue par combinaison d'une dose therapeutique efficace
 d'un compose de l'invention et d'un excipient pharmaceutiquement
 acceptable. Cette invention concerne aussi un procede de production
 d'une composition pharmaceutique consistant a combiner une dose
 therapeutique efficace d'un compose de l'invention et d'un excipient
 pharmaceutiquement acceptable. De plus, l'invention concerne une methode
 de traitement d'un sujet souffrant de depression et/ou
 d'anxiete consistant a administrer a ce dernier une dose d'un compose de
 l'invention efficace pour traiter la depression et/ou
 l'anxiete du sujet. En outre, cette invention concerne une methode de
 traitement de la depression et/ou de l'anxiete chez un sujet
 consistant a lui administrer une composition contenant un excipient
 pharmaceutiquement acceptable ainsi qu'une dose therapeutique efficace
 d'un antagoniste du recepteur GAL3.
 AN 2002060392 PCTFULL ED 20020815 EW 200232 <<LOGINID::20070205>>
 TIEN USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION
 AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS
 TIFR UTILISATION D'ANTAGONISTES DU RECEPTEUR GAL3 DANS LE TRAITEMENT DE LA
 DEPRESSION ET/OU DE L'ANXIETE ET COMPOSES UTILES DANS DE TELLES
 METHODES
 IN BLACKBURN, Thomas, P., 1 Fourteenth Street, Apt. 412, Hoboken, NJ 07030,
 US;
 KONKEL, Michael, 69 MacArthur Avenue, Garfield, NJ 07026, US
 PA SYNAPTIC PHARMACEUTICAL CORPORATION, 215 College Road, Paramus, NJ
 07652, US [US, US]
 AG WHITE, John, P., Cooper & Dunham LLP, 1185 Avenue of the Americas, New
 York, NY 10036, US
 LAF English
 LA English
 DT Patent

PI WO 2002060392 A2 20020808
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU
CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN
IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM
TN TR TT TZ UA UG UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
PRAI US 2001-09/775,341 20010131
AI WO 2002-US4608 A 20020131

L13 ANSWER 33 OF 33 PCTFULL COPYRIGHT 2007 Univentio on STN
TIEN TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS
TIFR TRAITEMENT DE LA SCHIZOPHRENIE PAR AMPAKINES ET NEUROLEPTIQUES
ABEN This invention relates to treatment of schizophrenia and related
psychotic disorders, including
enhancement of receptor functioning in synapses in brain networks
responsible for higher order
behaviors. In a particular aspect, the invention relates to methods for
the use of AMPA receptor
up-modulators in conjunction with antipsychotics for the treatment of
schizophrenia. Kits containing
the compositions in appropriate form for administration are also
provided. The figure shows that a
representative Ampakine (CX516) synergistically enhances clozapine
antagonism of
methamphetamine-induced rearing activity.

ABFR L'invention concerne un traitement de la schizophrénie et des troubles
psychotiques associés,
produisant une amélioration du fonctionnement des récepteurs synaptiques
des circuits neuronaux
responsables des comportements d'ordre supérieur. Dans un aspect
particulier, l'invention concerne
des méthodes de traitement de la schizophrénie comprenant l'utilisation
de stimulants du récepteur
AMPA associés à des antipsychotiques. L'invention concerne en outre des
kits comprenant ces
compositions présentées sous une forme appropriée à l'administration. Le
dessin montre qu'une
ampakine (Cx516) améliore synergiquement l'antagonisme de la clozapine
de l'activité de culture
induite par méthamphetamine.

AN 1999021422 PCTFULL ED 20020515 <<LOGINID::20070205>>
TIEN TREATMENT OF SCHIZOPHRENIA WITH AMPAKINES AND NEUROLEPTICS
TIFR TRAITEMENT DE LA SCHIZOPHRENIE PAR AMPAKINES ET NEUROLEPTIQUES
IN JOHNSON, Steven, A.;
ROGERS, Gary, A.;
LYNCH, Gary, S.
PA CORTEX PHARMACEUTICALS, INC.;
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;
JOHNSON, Steven, A.;
ROGERS, Gary, A.;
LYNCH, Gary, S.

LA English
DT Patent

PI WO 9921422 A1 19990506
DS W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS
MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE
DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

GA GN GW ML MR NE SN TD TG

PRAI	US 1997-60/063,627	19971027
AI	WO 1998-US22707	A 19981026